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Purpose/Background: Chemoradiotherapy (CRT) is often employed to treat locally advanced rectal cancer
with highly variable response, emphasizing the necessity for predictive response biomarkers. Our initial
proteomic and immunihistochemical work demonstrated that acid ceramidase (AC) expression correlated with
poorer CRT responses in rectal cancer. We described that higher AC expression correlates with
radioresistance in colorectal cancer cells and improved radiosensitivity through siRNA inhibition of AC. The
mechanisms behind AC expression, radioresistance and apoptosis remain unknown in colorectal cancer. AC is
known to affect apoptosis and the enzyme poly (ADP-ribose) polymerase-1 (PARP-1) is a DNA repair enzyme
that is also cleaved into specific fragments during apoptosis.
Aims: To elucidate a potential mechanism linking AC expression with radioresistance in colorectal cancer
cells.
Methods/Interventions: Differential AC protein expression of four colorectal cell lines was confirmed by
Western blotting. Radiosensitivity of these cell lines was examined using standard clonogenic assays by
counting individual colony survival post-exposure to increasing doses of ionizing radiation. siRNA knockdown
of AC was performed with further clonogenic assays to establish the impact of AC inhibition on radiosensitivity.
HT29 and HCT cells were then treated with non-targeting control siRNA and AC siRNA, irradiated at increased
doses of radiation then harvested at specific time points (2,6,24h). Western blotting was then performed to
detect the presence of specific PARP-1 cleavage fragments in the different treatments as specific apoptotic
markers.
Results/Outcome(s): Clonogenic assays confirmed that cell lines with greater cellular AC protein expression
(LIM 1215/MDST8) demonstrated higher colony survival compared to those with lower AC expression
(HT29/HCT 116) post irradiation. siRNA AC knockdown improved radiosensitivity by reducing colony formation
efficiency (CFE) in three cell lines: HT29 (0.52 CFE control vs 0.13 CFE knockdown at 1G p=0.00004); HCT
(0.24 CFE control vs 0.09 CFE knockdown at 1Gy p=0.026); LIM 1215 (0.88 CFE control vs 0.43 CFE
knockdown at 0.25Gy p=0.001). Western blotting confirmed that HT29 and HCT cells treated with AC siRNA
displayed significantly higher levels of the 24kD PARP-1 cleavage compared to control therefore indicating
increased apoptosis.
Conclusions/Discussion: Higher AC expression correlates with radioresistance in multiple colorectal cell
lines and we successfully improved radiosensitivity through biological (siRNA) inhibition of AC. Initial
mechanistic work has confirmed that siRNA inhibition of AC causes increased apoptosis in HT29 and HCT
cells following ionizing radiation, suggesting a role of AC expression and radioresistance through reduction in
apoptosis. Further work is required which could potentially allow AC to serve as a predictive CRT response
biomarker in rectal cancer patients.
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